KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EBITDA: 2018-2025

Historic EBITDA for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -$31.3 million.

  • Esperion Therapeutics' EBITDA fell 6.13% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$105.8 million, marking a year-over-year decrease of 21.97%. This contributed to the annual value of -$51.7 million for FY2024, which is 75.27% up from last year.
  • Per Esperion Therapeutics' latest filing, its EBITDA stood at -$31.3 million for Q3 2025, which was down 146.23% from -$12.7 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' EBITDA ranged from a high of $61.0 million in Q1 2024 and a low of -$90.9 million during Q1 2021.
  • Moreover, its 3-year median value for EBITDA was -$40.5 million (2025), whereas its average is -$31.4 million.
  • In the last 5 years, Esperion Therapeutics' EBITDA surged by 198.87% in 2024 and then slumped by 166.30% in 2025.
  • Over the past 5 years, Esperion Therapeutics' EBITDA (Quarterly) stood at -$65.2 million in 2021, then increased by 14.97% to -$55.4 million in 2022, then decreased by 1.71% to -$56.3 million in 2023, then soared by 62.16% to -$21.3 million in 2024, then dropped by 6.13% to -$31.3 million in 2025.
  • Its last three reported values are -$31.3 million in Q3 2025, -$12.7 million for Q2 2025, and -$40.5 million during Q1 2025.